Early stage cancer biotech Precision BioSciences files for a $100 million IPO
Precision BioSciences, an early stage cancer biotech developing gene-edited Car T Cell therapies, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Durham, NC-based company was founded in 2006 and booked $11 million in collaboration revenue for the 12 months ended December 31, 2018. It plans to list on the Nasdaq under the symbol DTIL. Precision BioSciences filed confidentially on October 19, 2018. J.P. Morgan, Goldman Sachs, Jefferies and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.
The article Early stage cancer biotech Precision BioSciences files for a $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.